Covid-19

Covid-19 has exacerbated the health inequities of many communities across the nation, and Dallas County is no exception. Fred Cerise, CEO of Parkland, and Steve Miff, president and CEO of Parkland's Center for Clinical Innovation, joined the Radio Advisory podcast to discuss why and how they are addressing inequities in Covid-19 vaccinations.

The FDA is expected to authorize Johnson & Johnson's coronavirus vaccine for emergency use later today—but is it truly safe and effective? Brandi Greenberg once again dives deep into the details to find out.

We all want to know when life will return to "normal". Advisory Board's Brandi Greenberg revisits three potential scenarios, the likelihood of each one, and how recent developments have changed her initial projections.

Health systems have had no shortage of challenges over the last year—and now, they face the added challenge of an increasingly complex vaccine rollout, one that requires ongoing coordination with a wide variety of external stakeholders, from public health agencies, to pharmaceutical companies, to tech companies, and more.

Christopher Kerms and Solomon Banjo examine the recent decline of Covid-19 cases in the U.S. and take a deep dive into the state of vaccinations, including efforts to vaccinate historically disenfranchised and rural patients.

Johnson & Johnson and Novavax separately released preliminary clinical trial data on their Covid-19 vaccine candidates. Here's what the data shows—and what it could mean for America's coronavirus epidemic, according to experts.

FDA has just authorized a coronavirus vaccine created by Pfizer and BioNTech, and tens of millions of doses will begin rolling out within days. We now know enough to answer some of our lingering questions—and to draw conclusions about the effectiveness both of FDA's review process and of the vaccine itself.

Moderna’s vaccine was also authorized for emergency use in December 2020. Brandi Greenberg again answered our 8 biggest questions about the safety and efficacy of this vaccine, and also discussed how it compares to the Pfizer vaccine.

We spoke with Moderna’s CEO about how his company designed a coronavirus vaccine in just two days, how his team collaborated with Operation Warp Speed, and his plan to develop vaccines against potentially deadly viruses before they strike humans.

We spoke with the CEO of Johnson and Johnson about how his company developed a vaccine in "months rather than years," why he's more interested in cultivating a "sustainable innovation culture" than ironing out a 30-year strategic plan, the trend he thinks will be "ubiquitous across health care going forward," and more.